Profil
Jeroen van Beek worked as a Marketing Director at Pfizer Inc. from 1999 to 2007.
He then worked as VP-Global Commercial Operations & Development at Alexion Pharmaceuticals, Inc. from 2007 to 2017.
In 2018, he briefly worked as Chief Commercial Officer & Senior Vice President at Tricida, Inc. From 2019 to 2022, he worked as Chief Commercial Officer & Executive VP at AlloVir, Inc. Dr. van Beek received his undergraduate degree from the University of Virginia, his doctorate from Cornell University, and his MBA from the University of Virginia Darden School of Business.
Ehemalige bekannte Positionen von Jeroen van Beek
| Unternehmen | Position | Ende |
|---|---|---|
| ALLOVIR, INC. | Corporate Officer/Principal | 23.11.2022 |
| TRICIDA, INC. | Corporate Officer/Principal | 31.08.2018 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2017 |
| PFIZER, INC. | Vertrieb & Marketing | 01.01.2007 |
Ausbildung von Jeroen van Beek
| Cornell University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| TRICIDA, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
